Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 1,044,301 |
|
|||||
| News | - | ||||||
| Day High | 2.10 | Low High |
|||||
| Day Low | 1.50 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Renovaro Inc | RENB | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.25 | -14.71% | 1.45 | 23:00:06 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.79 | 1.50 | 2.10 | 1.53 | 1.70 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 5,093 | 1,044,301 | US$ 1.71 | US$ 1,784,731 | - | 0.6601 - 5.25 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:53:55 | 3 | US$ 1.48 | USD |
Renovaro Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 222.69M | 143.67M | - | 0 | -39.68M | -0.28 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Renovaro News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RENB Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.28 | 2.28 | 1.50 | 1.94 | 249,276 | -0.83 | -36.40% |
| 1 Month | 2.66 | 3.05 | 1.50 | 2.36 | 204,115 | -1.21 | -45.49% |
| 3 Months | 4.41 | 4.45 | 1.50 | 2.73 | 325,077 | -2.96 | -67.12% |
| 6 Months | 2.89 | 5.25 | 1.50 | 3.02 | 210,093 | -1.44 | -49.83% |
| 1 Year | 0.87 | 5.25 | 0.6601 | 2.33 | 448,958 | 0.58 | 66.67% |
| 3 Years | 0.87 | 5.25 | 0.6601 | 2.33 | 448,958 | 0.58 | 66.67% |
| 5 Years | 0.87 | 5.25 | 0.6601 | 2.33 | 448,958 | 0.58 | 66.67% |
Renovaro Description
| Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. |
